Loading
A phase 3 trial in lung cancer, run by Qinghai Red Cross Hospital, now recruiting.
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer is a phase 3, randomised interventional study registered as NCT06338683 by Qinghai Red Cross Hospital, with a registry enrolment figure of 230 participants, started 2024-03-20 and due to reach its primary completion in 2027-03-20. Interventions recorded: Olanzapine 2.5 MG; Standard anti-tumor treatment; Nutritional advice. Conditions listed: Advanced Cancer; Olanzapine; Progression Free Survival. Primary outcome: Comparing the difference in Median PFS between the two groups. Lung eligibility wording from the registry: "Stage III or IV inoperable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer and lung cancer confirmed by histology or cytology;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.